GENB · Insider Trading
Generate Biomedicines, Inc. Common Stock
Every open-market purchase and sale reported by GENB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Frances Arnold | Director | Sell | −1,000 | −$16.00K |
| 2026-03-06 | Michael Nally | Chief Executive Officer | Buy | +20,000 | +$240.00K |
| 2026-03-02 | Beth Grous | Chief People Officer | Buy | +300 | +$4.80K |
| 2026-03-02 | Paul Gray Parker | Director | A | +29,561 deriv. | — |
| 2026-03-02 | Nancy A Simonian | Director | A | +29,561 deriv. | — |
| 2026-03-02 | Frances Arnold | Director | A | +29,561 deriv. | — |
| 2026-03-02 | Marsha Fanucci | Director | A | +29,561 deriv. | — |
| 2026-03-02 | Rupert Vessey | Director | A | +29,561 deriv. | — |
| 2026-03-02 | Laurie Anne Lee | Chief Medical Officer | A | +42,230 deriv. | — |
| 2026-03-02 | Jane L Mendillo | Director | Buy | +1,500 | +$24.00K |
| 2026-03-02 | Jason Silvers | President & CFO | Buy | +1,500 | +$24.00K |
| 2026-03-02 | Stephane Bancel | Director | C | +724,160 | — |
| 2026-03-02 | Sean Martin | Chief Legal Officer & GC | A | +190,034 deriv. | — |
| 2026-03-02 | Michael Nally | Chief Executive Officer | C | +658,327 | — |
| 2026-03-02 | Gevorg Grigoryan | Chief Technology Officer | A | +491,976 deriv. | — |
| 2026-03-02 | Flagship Pioneering Fund VI, L.P. | 10%+ Owner | MIXED | +263,596,613 | +$525.00M |
| 2026-03-02 | FPN General Partner LLC | 10%+ Owner | MIXED | +301,253,272 | +$600.00M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| FPN General Partner LLC | 10%+ Owner | 4,340,252 | $53.60M |
| Flagship Pioneering Fund VI, L.P. | 10%+ Owner | 2,777,752 | $34.31M |
| Michael Nally | Chief Executive Officer | 1,889,361 | $23.33M |
| Stephane Bancel | Director | 1,184,989 | $14.63M |
| Frances Arnold | Director | 463,944 | $5.73M |
| Jane L Mendillo | Director | 1,500 | $18.52K |
| Jason Silvers | President & CFO | 1,000 | $12.35K |
| Beth Grous | Chief People Officer | 300 | $3.71K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GENB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.